Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL59276

Cc1ccc(NC(=O)Nc2ccc(-c3cc(CN4CCOCC4)n4ncnc(N)c34)cc2)cc1C.O=C(O)C(F)(F)F

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACVRL1 P37023 8/20 0.60
MERTK Q12866 1/20 0.55
FLT3 P36888 6/20 0.44
KIT P10721 4/20 0.44
KDR P35968 4/20 0.44
RET P07949 2/20 0.44
FGFR1 P11362 2/20 0.44
FRK P42685 2/20 0.44
RPS6KA3 P51812 2/20 0.44
PRKCD Q05655 2/20 0.44
MAP4K2 Q12851 2/20 0.44
BCR P11274 1/20 0.44
MAPK9 P45984 1/20 0.44
DDR1 Q08345 1/20 0.44
TNK1 Q13470 1/20 0.44
RPS6KA1 Q15418 1/20 0.44
MAP3K11 Q16584 1/20 0.44
DDR2 Q16832 1/20 0.44
RPS6KA6 Q9UK32 1/20 0.44
TEK Q02763 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL59783 0.95 ACVRL1 (0.66) ACVRL1MERTKFLT3KITKDR
Trifluoroacetic Acid SCHEMBL841675 0.94 ACVRL1 (0.58) ACVRL1MERTKFLT3KITKDR
Trifluoroacetic Acid SCHEMBL59541 0.92 ACVRL1 (0.59) ACVRL1MERTKFLT3KITKDR
Trifluoroacetic Acid SCHEMBL57718 0.89 ACVRL1 (0.56) ACVRL1MERTKFLT3KITKDR
SCHEMBL58954 0.88 ACVRL1 (0.64) ACVRL1MERTKFLT3KITKDR
SCHEMBL878975 0.88 ACVRL1 (0.63) ACVRL1MERTKFLT3KITKDR
Trifluoroacetic Acid SCHEMBL27747125 0.87 ACVRL1 (0.63) ACVRL1MERTKFLT3KITKDR
SCHEMBL59916 0.86 ACVRL1 (0.66) ACVRL1MERTKFLT3KITKDR
SCHEMBL59277 0.86 ACVRL1 (0.56) ACVRL1MERTKFLT3KITKDR
SCHEMBL58915 0.85 ACVRL1 (0.62) ACVRL1MERTKFLT3KITKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957485-B1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE LLC (US) 2013-02-13 EP claimed
US-8143393-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-27 US claimed
US-20100179125-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE LLC (US) 2010-07-15 US claimed
US-20100063038-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis BAYER HEALTHCARE LLC 2010-03-11 US claimed
EP-1957485-B1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE LLC (US) 2013-02-13 EP disclosed
US-8143393-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-27 US disclosed
US-8129379-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-06 US disclosed
US-20100179125-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE LLC (US) 2010-07-15 US disclosed
US-20100063038-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis BAYER HEALTHCARE LLC 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179125-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS CDK4, CDKL4, MKI67 ACVRL1 941/4885MERTK 1749/4885FLT3 271/4885
US-20100063038-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis CDK4, CDKL4, MKI67 ACVRL1 963/4885MERTK 1905/4885FLT3 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.